VIIV HLTHCARE Company Profile

✉ Email this page to a colleague

VIIV HLTHCARE has twenty-six approved drugs.

There are twelve US patents protecting VIIV HLTHCARE drugs.

There are five hundred and fourteen patent family members on VIIV HLTHCARE drugs in fifty-nine countries and two hundred and eleven supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950-001	Jul 2, 2020		RX	Yes	Yes	7,745,625	⤷ Try a Trial		Y		⤷ Try a Trial
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-003	Jun 9, 2016		DISCN	Yes	No	9,242,986*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Viiv Hlthcare	SELZENTRY	maraviroc	TABLET;ORAL	022128-003	Nov 4, 2016		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RETROVIR	zidovudine	TABLET;ORAL	020518-002	Oct 4, 1996	4,724,232	⤷ Try a Trial
Viiv Hlthcare	ZIAGEN	abacavir sulfate	SOLUTION;ORAL	020978-001	Dec 17, 1998	6,294,978*PED	⤷ Try a Trial
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	SUSPENSION;ORAL	022116-001	Jun 14, 2007	6,436,989*PED	⤷ Try a Trial
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017	7,067,522	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2011-11-22
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2009-01-28
➤ Subscribe	Tablets	700 mg	➤ Subscribe	2012-01-18
➤ Subscribe	Tablets	600 mg/300 mg	➤ Subscribe	2007-09-27
➤ Subscribe	Tablets	600 mg/50 mg/300 mg	➤ Subscribe	2017-08-14
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2011-08-08
➤ Subscribe	Oral Solution	20 mg/ml	➤ Subscribe	2012-12-27
➤ Subscribe	Tablets	150 mg/300 mg	➤ Subscribe	2007-06-26
➤ Subscribe	Tablets	10 mg, 25 mg and 50 mg	➤ Subscribe	2017-08-14
➤ Subscribe	Tablets	300 mg/150 mg/300 mg	➤ Subscribe	2011-03-22

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1632232	300852	Netherlands	⤷ Try a Trial	PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINEHYDROCHLORIDE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI; - EMTRICITABINE; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623
1284974	PA2008004	Lithuania	⤷ Try a Trial	PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
1419152	2012C/022	Belgium	⤷ Try a Trial	PRODUCT NAME: RILPIVIRINE EN TENOFOVIR DISOPROXIL; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001 20111128
1663240	92855	Luxembourg	⤷ Try a Trial	PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE , TENOFOVIR, EN PARTICULIER LE FUMARATE DE TENOFOVIR DISOPROXIL, ET L'EMTRICITABINE.
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.